Phaseline

Companies › USWM CT

USWM CT: clinical trials, targets and expected readouts

4 active drug programs in 6 registered trials: 3 Phase 1, 3 Phase 2; Oncology; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
letetresgene autoleucel (lete-cel, GSK3377794)
genetically engineered T cells targeting NY-ESO-1 (CTAG1B) and LAGE-1a
CTAG1B, LAGE1Phase 2NeoplasmsJul 2028
ADP-A2M4CD8
Autologous genetically modified T-cell therapy targeting MAGE-A4 in HLA-A2+ patients
–Phase 2Ovarian Cancer; Endometrial CancerApr 2037
Afamitresgene Autoleucel
Melanoma-associated antigen 4 binding agent
MAGEA4Phase 2Synovial SarcomaApr 2038
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
T cell receptor (TCR) engineered T cells targeting MAGE-A4
MAGE-A4Phase 1Urinary Bladder CancerSep 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05601752ADP-A2M4CD8Phase 2Ovarian CancerOncologySep 2025
NCT03967223letetresgene autoleucel (lete-cel, GSK3377794)Phase 2NeoplasmsOncologyJul 2028
NCT03132922Autologous genetically modified MAGE-A4ᶜ¹º³²T cellsPhase 1Urinary Bladder CancerOncologySep 2032
NCT04044859ADP-A2M4CD8Phase 1Endometrial CancerOncologyApr 2037
NCT04044768Afamitresgene AutoleucelPhase 2Synovial SarcomaOncologyApr 2038
NCT05642455Afamitresgene AutoleucelPhase 1Synovial SarcomaOncologyJul 2038

Targets

MAGE-A4 (1) MAGEA4 (1) CTAG1B (1) LAGE1 (1)

Companies with the same targets

Immatics Biotechnologies Zelluna Immunotherapy PDC*line Pharma SAS CDR-Life

Companies built like this

CNBG-Virogin Biotech (Shanghai) Stella Pharma Dendreon Hrain Biotechnology Marzieh Ebrahimi

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.